Visit Patient Site
Contact Abbott
English
Get Support Kit
Get Support Kit

Better outcomes. Clinically proven in patients with T1D and T2D.1-3

Both real-world evidence and clinical trial results show improved outcomes with the FreeStyle Libre 2 system.1-3

Proven outcomes

Associated with a 0.9% reduction in A1C4 (p<0.0001)


T2D real-world study results: 

  • Patients on long-acting (basal) insulin:

    • Associated with a 1.1% reduction in A1C (from 10.1% at baseline to 9.0%; p<0.001)4

  • Patients on non-insulin therapies:

    • Associated with a 1.6% reduction in A1C (from 10.1% at baseline to 8.5%; p<0.001)4

  • Patients with poor glycemic control (baseline A1C ≥12%):

    • Associated with a 3.7% reduction in A1C (from 13.1% at baseline to 9.4%; p<0.001)4

Associated with a 43% increase in time in target range

(3.9-10.0 mmol/L) from 11.7 to 16.8 hours a day with increased scan rate 
(p<0.001)5

Associated with a 63% reduction in time spent above 13.3 mmol/L

across patients with diabetes5 (p<0.001) 

Associated with a 43% reduction in time spent <3.9 mmol/L

in patients with T2D (p<0.001)6

Patients with T1D and T2D using the system:

  • 95% report a better understanding of their glucose fluctuations7

  • 92% find it easier to regulate their glucose around a meal7

0.4% reduction in A1C8

Increased time in target range by 1 hour/day8

(3.9-10.0 mmol/L) 

Reduced time spent in hyperglycemia (>10 mmol/L) by 1 hour/day

with no significant increase in time spent in hypoglycemia (<3.9 mmol/L).8

Increased the frequency of glucose monitoring to an average of 8x per day

vs. CBG.8

Increased monitoring means improved self-management9

Clinically proven accuracy10

Excellent accuracy at a glance

9.2%

Overall MARD10

The lower the MARD, the more accurate the results 

99.9%

in zones A+B  

of consensus error grid10

Measurement errors associated with these zones have no effect on clinical action, and little or no effect on clinical outcomes.10

Trusted accuracy, even when glucose is low, falling or rapidly changing.10

  • Outstanding accuracy in the low glucose range (<3.9 mmol/L)10

  • 98.8% of results for levels <3.9 mmol/L are within ±1.1 mmol/L of blood glucose measurements11

Clinically proven to be accurate10 over 14 days in pediatric patients

9.7%

Overall MARD

The lower the MARD, the more accurate the results10

100%

in zones A+B  

of consensus error grid10

Measurement errors associated with these zones have no effect on clinical action, and little or no effect on clinical outcomes.10

Outstanding low-end accuracy where it matters most10

  • Low glucose range (<3.9 mmol/L)

  • 98.8% of results in this range are within ±1.1 mmol/L of blood glucose measures11

Parents and caregivers can rely on the FreeStyle Libre 2 system to make treatment decisions even when glucose is low, falling or rapidly changing.

CBG=capillary blood glucose; MARD=mean absolute relative difference; YSI=Yellow Springs Instrument.
The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check the website for more information about device compatibility before using the app. Use of FreeStyle Libre 2 app requires registration with LibreView.

References:

  1. Evans M, Welsh Z, Seibold A. Reductions in HbA1c with Flash Glucose Monitoring Are Sustained for up to 24 Months: A Meta-Analysis of 75 Real-World Observational Studies. Diabetes Ther. 2022;13(6):1175-1185. doi:10.1007/s13300-022-01253-9.
  2. Bolinder J, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016;388(10057):2254-2263. doi:10.1016/S0140-6736(16)31535-5.
  3. Roussel R, et al. Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study. Diabetes Care. 2021;44(6):1368-1376. doi:10.2337/dc20-1690.
  4. Wright EE Jr, et al. Use of flash glucose monitoring is associated with A1C reduction in people with type 2 diabetes treated with basal insulin or noninsulin therapy. Diabetes Spectr 2021;34(2):184-89.
  5. Lang J, et al. Expanded real-world use confirms strong association between frequency of flash glucose monitoring and glucose control [Abstract 089]. Diabetes Technol Ther 2019;21(1):A40.
  6. Haak T, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8(1):55-73.
  7. Fokkert M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diabetes Res Care 2019;7(1):e000809.
  8. Campbell FM, et al. Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. Pediatr Diabetes 2018;19(7):1294-301.
  9. Aronson R, et al. IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trial. Diabetes Obes Metab. 2023;25(4):1024‐1031. doi:10.1111/dom.14949.
  10. Alva S, et al. Accuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System With Advanced Algorithm in Pediatric and Adult Population With Diabetes. J Diabetes Sci Technol. 2022;16(1):70-77. doi:10.1177/1932296820958754.
  11. Data on file, Abbott Diabetes Care, Inc.

This site is intended for Canadian Healthcare Professionals only. Visit patient site.

The FreeStyle Libre 2 flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in people aged 4 years and older with diabetes mellitus. Always read and follow the label/insert.

Why Sensor-based Glucose Monitoring?
About FreeStyle Libre
How to Prescribe
LibreView
Clinic Resources
Abbott. life. to the fullest

© 2025 Abbott
The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Product images are for illustrative purposes only. Other trademarks are the property of their respective owners.
ADC-64590 v5.0

You’re now leaving an Abbott Canada website, a site maintained by Abbott

You are now being redirected to a third-party website not under the control of Abbott. Abbott is not responsible for the contents of such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply the endorsement of the linked site by Abbott.

Do you wish to leave this site?

Disclaimer

EasytoFreeStyle.ca is a product-specific website intended only for residents of Canada.

If you are a resident of another country, please visit our global directory to locate the appropriate site for your country.